GLPwatch
Papers (12034)
Page 163 of 201, ranked by citation count.
- [Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?].
- Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study.
- Incretin physiology and its role in type 2 diabetes mellitus.
- The Effect of Semaglutide on Pancreatic β-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.
- Semaglutide for the treatment of MASH: reaching into the ESSENCE of cardio-metabolic health?
- Risk stratification using coronary artery calcium and potential benefit of semaglutide therapy: A cost-effectiveness modelling study.
- Is Semaglutide a Safer Weight-Management Option Than Bariatric Surgery for Patients Undergoing Total Hip Arthroplasty (THA)?
- Comment on "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients".
- Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study.
- Usefulness of circulating EPAC1 as biomarkers of therapeutic response to GLP-1 receptor agonists.
- [Incretin analogues as a novel treatment strategy for Alzheimer's disease].
- Semaglutide-associated drug-induced liver injury: a case report and review of the literature.
- Novel finding of pulmonary embolism following tirzepatide (Manjaro) use in a young adult without risk factors of venous thromboembolic events.
- Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.
- New therapeutic options: management strategies to optimize glycemic control.
- Multidimensional Predictors of Tirzepatide Efficacy: Clinical, Genetic, and Molecular Biomarkers for Glycemic, Weight, and Organ Protection.
- An analysis of national news coverage of semaglutide for weight loss.
- Role of glucagon-like peptide-1 receptor agonists in pediatric obesity and metabolic dysfunction associated steatotic liver disease.
- National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss.
- SOUL searching in GLP-1 therapy: Oral semaglutide confirms cardioprotection in type 2 diabetes.
- Trends and projections of overweight and obesity among midlife women in the United States, 1990-2050: A sub‑study of the Global Burden of Disease 2021.
- The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults.
- Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
- Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.
- Intranasal Human Recombinant Modified Glucagon-Like Peptide-1: High Antihyperglycemic Activity and Duration of Action in Mice.
- GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study.
- Ketoacidosis associated with tirzepatide use in a nonobese individual without diabetes.
- Pharmacist-led management of GLP-1 and GIP/GLP-1 receptor agonists in type 2 diabetes mellitus.
- Starvation ketoacidosis associated with tirzepatide use for weight loss in a non-diabetic East Asian woman: a case report.
- Sex specific responses to oral vs. subcutaneous semaglutide in type 2 diabetes mellitus: A 12-month real-world study.
- Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report.
- [Successful treatment of KCNJ11 neonatal diabetes without insulin].
- Various GLP-1 Receptor Agonist Preference Use with a Special Focus on Oral and Subcutaneous Forms in Poland.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
- Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetes.
- Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis.
- GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs.
- The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case-control study.
- Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.
- Exposure-adjusted safety and efficacy of GLP-I and GLP-1/GIP receptor agonists compared with non-GLP-I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects.
- Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders.
- Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events.
- Some Risks of Gastrointestinal Adverse Events Associated With Glucagon-Like PEPTIDE-1 Receptor Agonists Are Likely Explained by BMI.
- Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus.
- Therapy Combining Glucagon-Like Peptide-1 Receptor Agonist with Sodium-Glucose Cotransporter 2 Inhibitor Suppresses Atherosclerosis in Diabetic ApoE-Deficient Mice.
- Synthesis of the extracellular domain of GLP-1R by chemical and biotechnological approaches.
- Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports.
- The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis.
- Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial.
- Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study.
- Exenatide Is Neuroprotective in a New Rabbit Model of Hypoxia-Ischemia.
- Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects.
- Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.
- Cardiorenal benefits of glucagon-like peptide-1 analogues vs. exendin-4 analogues in patients with type 2 diabetes: a meta-analysis based on cardiovascular outcome trials.
- CCK Response Deficiency in Synphilin-1 Transgenic Mice.
- Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data.
- EHR Data Suggest Tirzepatide Outdoes Semaglutide for Weight Loss.
- Outcomes of Semaglutide Use in Achieving Target Body Mass Index Before Renal Transplant in Five End-Stage Renal Disease Patients: A Case Series.
- Effects of Tirzepatide on Body Composition, Metabolic Parameters, and Sleep Outcomes: A Real-World One-Year Prospective Study.